Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | TNKS | O95271 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.43 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Maleic Acid SCHEMBL7194412 | 1.00 | TSHR (0.62) | TSHRALDH1A1HCAR2HDAC3TNKS | |
| Bicarbonate SCHEMBL28650787 | 0.87 | TSHR (0.75) | TSHRALDH1A1HDAC3HDAC1HDAC2 | |
| Maleic Acid SCHEMBL11361008 | 0.84 | SMN1; SMN2 (0.53) | TSHRALDH1A1HCAR2HDAC3TNKS | |
| Fumaric Acid SCHEMBL5478623 | 0.84 | TSHR (0.47) | TSHRALDH1A1HCAR2MAPTPOLB | |
| Acetic Acid SCHEMBL7836902 | 0.83 | TSHR (0.68) | TSHRALDH1A1MAPTPOLBRECQL | |
| Formic Acid SCHEMBL27489350 | 0.80 | TSHR (0.71) | TSHRALDH1A1HDAC1POLBRECQL | |
| Benzene SCHEMBL27633873 | 0.79 | TSHR (0.88) | TSHRALDH1A1TP53HSD17B10LMNA | |
| Glycine SCHEMBL27900643 | 0.79 | TSHR (0.62) | TSHRALDH1A1MAPTPOLBRECQL | |
| SCHEMBL25495 | 0.79 | — | — | |
| SCHEMBL29472208 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2431028-B1 | FAST-DISSOLVING ORAL FILM FOR EFFECTIVELY CONCEALING UNPLEASANT TASTES | CHABIO & DIOSTECH CO LTD (KR) | 2017-07-12 | — | — | EP | claimed |
| US-9492379-B2 | Quickly soluble oral film dosage containing steviosides as a unpleasant taste masking agent | CHABIO & DIOSTECH CO., LTD. (KR) | 2016-11-15 | — | — | US | claimed |
| US-20130039932-A1 | QUICKLY SOLUBLE ORAL FILM DOSAGE CONTAINING STEVIOSIDES AS A UNPLEASANT TASTE MASKING AGENT | CHABIO & DIOSTECH CO., LTD. (KR) | 2013-02-14 | — | — | US | claimed |
| WO-2012134770-A1 | HONEY COMPOSITION | AVERY DENNISON CORPORATION (US) | 2012-10-04 | — | — | WO | claimed |
| US-20120156229-A1 | QUICKLY SOLUBLE ORAL FILM DOSAGE CONTAINING STEVIOSIDES AS A UNPLEASANT TASTE MASKING AGENT | CHABIO & DIOSTECH CO. LTD (KR) | 2012-06-21 | — | — | US | claimed |
| EP-2431028-A2 | FAST-DISSOLVING ORAL FILM FOR EFFECTIVELY CONCEALING UNPLEASANT TASTES | Chabio & Diostech Co., Ltd. (KR) | 2012-03-21 | — | — | EP | claimed |
| US-20070196504-A1 | PHARMACEUTICAL COMPOSITION | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-08-23 | — | — | US | claimed |
| US-20040022848-A1 | Medicinal composition | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-02-05 | — | — | US | claimed |
| EP-1319399-A1 | MEDICINAL COMPOSITION | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-06-18 | — | — | EP | claimed |
| EP-0254978-A1 | Substained-release drug preparation | Eisai Co., Ltd. (JP) | 1988-02-03 | — | — | EP | claimed |
| US-20250262097-A1 | MEDICAL DRESSINGS AND USES THEREOF | MARINE BIOLOGY & ENVIRONMENTAL TECHNOLOGIES, LLC (US) | 2025-08-21 | — | — | US | disclosed |
| US-12350352-B2 | Composition for surface modification | LG HOUSEHOLD & HEALTH CARE LTD. (KR) | 2025-07-08 | — | — | US | disclosed |
| US-12232934-B2 | Medical dressings and uses thereof | MARINE BIOLOGY & ENVIRONMENTAL TECHNOLOGIES, LLC (CA) | 2025-02-25 | — | — | US | disclosed |
| EP-3342395-B1 | COMPOSITION FOR HAIR SURFACE MODIFICATION | LG HOUSEHOLD & HEALTH CARE LTD (KR) | 2024-08-07 | — | — | EP | disclosed |
| EP-3115044-B1 | PATCH PREPARATION | TEIKOKU SEIYAKU KK (JP) | 2024-07-31 | — | — | EP | disclosed |
| US-4517173-A | TIME-RELEASE OF DRUGS IN THE MOUTH | NIPPON SODA CO. LTD. (JP) | 1985-05-14 | — | — | US | disclosed |
| EP-0081438-A2 | Adhesive bandage | NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) | 1983-06-15 | — | — | EP | disclosed |
| EP-0063604-A1 | MUCOUS MEMBRANE-ADHERING FILM PREPARATION AND PROCESS FOR ITS PREPARATION | NIPPON SODA CO., LTD. (JP) | 1982-11-03 | — | — | EP | disclosed |
| US-4130555-A | FOODS, COSMETICS | NIPPI INCORPORATED (JP) | 1978-12-19 | — | — | US | disclosed |
| US-4059686-A | SODIUM POLYACRYLATE | NIPPON KAYAKU KABUSHIKI KAISHA (JA) | 1977-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12350352-B2 | Composition for surface modification | CUTA, PTMS, DNMT1 | TSHR 3020/4885ALDH1A1 1329/4885HCAR2 1281/4885 |
| US-20040022848-A1 | Medicinal composition | CD44, CMA1, ACLY | TSHR 4674/4885ALDH1A1 1653/4885HCAR2 574/4885 |
| US-20070196504-A1 | PHARMACEUTICAL COMPOSITION | CMA1, HRH2, ACLY | TSHR 4318/4885ALDH1A1 2434/4885HCAR2 721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.